New hope for rare heart condition: drug aims to stop protein buildup
NCT ID NCT04843020
First seen Feb 21, 2026 · Last updated May 14, 2026 · Updated 13 times
Summary
This study tests an experimental drug called ION-682884 in people with a rare heart condition caused by abnormal protein deposits (TTR amyloidosis). The drug is designed to lower the production of this protein in the liver, potentially slowing or stopping heart damage. Only patients who completed a prior 24-month study of a similar drug (inotersen) can join. The study was withdrawn before enrolling anyone, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.